#USA #Lakewood #CDMO Services #LTS Lohmann #Ophthalmic Drug Delivery

LTS Expands CDMO Portfolio with Innovative Solutions for Ophthalmic Drug Delivery

LTS Lohmann Therapie-Systeme AG (LTS), a prominent player in pharmaceutical technology, has made a significant move by broadening its contract development and manufacturing organization (CDMO) services to include specialized ophthalmic drug delivery solutions. This expansion promises to revolutionize how ophthalmic medications are developed and provided, particularly through sterile products manufactured at LTS’s state-of-the-art facility in Lakewood, New Jersey, USA.

A New Horizon for Ophthalmic Treatments

Ophthalmic drug delivery systems are crucial in managing various eye conditions, from chronic issues to acute ailments. LTS focuses on delivering high-quality products specifically designed for these delicate treatments. The company’s experience in sterile product manufacturing, demonstrated through clinical production methods, positions it as a key player in the competitive market of ophthalmic solutions. The new offering will initially emphasize clinical manufacturing of preservative-free, multidose devices, which are essential in ensuring patient safety and comfort.

Bas van Buijtenen, CEO of LTS, expressed confidence in the company’s capabilities, stating, “Ophthalmic drug delivery presents unique challenges in terms of sterility, efficacy, and patient safety. Our aseptic manufacturing capabilities in Lakewood provide the perfect foundation to build leading CDMO capabilities and capacity for ophthalmics.” The integration of advanced technologies and facilities allows LTS to support both U.S. and international market requirements while remaining compliant with global regulatory standards.

Comprehensive End-to-End CDMO Services

LTS aims to offer comprehensive CDMO services for a full range of ophthalmic drug products, covering everything from formulation development to commercial manufacturing. This strategic move is designed to cater to the growing demand from pharmaceutical and biotech companies seeking reliable partners in the U.S. for manufacturing and developing ophthalmic solutions. By combining their extensive expertise in drug delivery systems with an unwavering commitment to quality, LTS seeks to forge long-term partnerships throughout the entire product lifecycle.

The expansion is not just an operational maneuver; it reflects LTS's strategic vision to adapt and grow alongside the evolving needs of the pharmaceutical industry. LTS is committed to its mission of enhancing patient care through innovative drug delivery solutions, driving advancements in how medications reach patients effectively and safely.

A Commitment to the Future

As LTS continues to build on its foundation of excellence, it emphasizes its core values in every aspect of its operations. The mantra, “We CARE. We CREATE. We DELIVER,” encapsulates their approach to fostering relationships with partners and customers alike, while aiming to improve health outcomes for patients worldwide. The addition of ophthalmic drug delivery solutions to their portfolio aligns closely with this ethos, ensuring a diversified range of services catered to the nuanced requirements of sensitive therapeutic areas.

In conclusion, LTS Lohmann Therapie-Systeme AG’s recent expansion into ophthalmic drug delivery CDMO services marks a pivotal step forward in pharmaceutical technology. By leveraging its established capabilities in sterile product manufacturing and commitment to innovation, LTS is well-positioned to make significant contributions to the field of ophthalmology and beyond, addressing the pressing needs of both healthcare providers and patients across the globe.

For more information on LTS's services and how they can partner with pharmaceutical companies, do not hesitate to get in touch directly at their corporate office.